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Abstract 
Retinoic	  acid	  (RA)	  is	  a	  small	  molecule	  capable	  of	  shunting	  developing	  T	  cells	  away	  
from	   the	   Th17	   lineage	   and	   towards	   the	   Treg	   phenotype,	   making	   it	   a	   potentially	  
useful	   therapeutic	   for	   autoimmune	  and	   inflammatory	  diseases.	   	  However,	   therapy	  
can	  be	  complicated	  by	  systemic	  toxicity	  and	  unpredictable	  bioavailability,	  making	  a	  
targeted	  drug	  delivery	  vehicle	  for	  local	  therapy	  desirable.	  	  A	  promising	  approach	  is	  
the	   use	   of	   nanoparticles,	  which	   have	   been	   demonstrated	   to	   increase	   potency	   and	  
decrease	   toxicity	   of	   therapies	   in	   a	   variety	   of	   disease	   models	   including	   Th17	  
mediated	   diseases.	   	   We	   therefore	   constructed	   a	   nanoparticulate	   drug	   delivery	  
platform	   from	   poly(lactic-­‐co-­‐glycolic	   acid)	   (PLGA)	   capable	   of	   encapsulating	   and	  
releasing	   RA.	   	   	   Here	   we	   report	   the	   fabrication,	   characterization,	   and	   in	   vitro	  
bioactivity	  of	  this	  platform.	  We	  demonstrate	  that	  RA	  containing	  PLGA	  nanoparticles	  
suppress	   IL-­‐17	   and	   IFN-­‐γ	   production	   and	  ROR-­‐γ(t)	   expression	   in	  T	   cells	   polarized	  
towards	   the	   Th17	   phenotype	   in	   vitro	   with	   similar	   potency	   to	   that	   of	   free	   drug.	  	  
Furthermore,	   we	   show	   that	   these	   particles	   enhance	   TGF-­‐β	   dependent	   Foxp3	  
expression	  and	  IL-­‐10	  production	  of	  T	  cells	  in	  vitro	  with	  similar	  potency	  to	  free	  RA.	  	  
Finally,	  we	  demonstrate	   that	  T	  cells	  polarized	   towards	   the	  Th17	  phenotype	   in	   the	  
presence	   of	   free	   RA	   and	   nanoparticulate	   RA	   have	   similarly	   suppressed	   ability	   to	  
induce	   IL-­‐6	  production	  by	   fibroblasts.	   	  Our	   findings	  demonstrate	   the	   feasibility	   of	  
RA	  delivery	  via	  biodegradable	  nanoparticles	   and	   represent	   an	   exciting	   technology	  
for	  the	  treatment	  of	  autoimmune	  and	  inflammatory	  diseases.	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1.1- Targeted Therapy 
The	   concept	   of	   targeted	   therapy	   is	   an	   old	   one.	   	   It	   was	   first	   formally	   proposed	   in	  
1906	   by	   the	   eminent	   physician	   Paul	   Ehrlich	   in	   which	   he	   imagined	   a	   drug	   that	  
selectively	   affected	   a	   specific	   diseased	   structure	   or	   pathological	   process	   to	   the	  
exclusion	  of	  all	  else1.	  	  As	  an	  early	  developer	  of	  chemotherapy	  for	  cancer	  treatment,	  
the	  appeal	  of	   a	   “magic-­‐bullet”	   that	   could	   cure	  disease	  without	   causing	   side	  effects	  
must	   have	   been	   immense.	   	   The	   concept	   of	   targeted	   therapy	   has	   broadened	   since	  
Ehrlich’s	   time	   to	   include	   therapies	   not	   only	   for	   cancer	   but	   any	   pharmacologic	  
treatment	  that	  has	  side	  effects.	  
	  
1.1.1- Therapeutic Targeting Strategies 
Vast	   improvements	   have	   been	  made	   in	   the	   development	   of	   targeted	   therapeutics	  
since	  the	  concept	  was	  first	  proposed	  over	  100	  years	  ago.	  	  Two	  strategies	  have	  been	  
identified	   to	   achieve	   targeted	  drug	  delivery-­‐	   pharmacologically	   targeted	   therapies	  
	   2	  
and	   local	   drug	   delivery2,3.	   	   Pharmacological	   targeting	   refers	   to	   the	   use	   of	   a	  
therapeutic	  that	  selectively	  affects	  a	  specific	  pathological	  process	  implicated	  in	  the	  
disease	   being	   treated	   with	   the	   hope	   that	   normal	   biological	   processes	   remain	  
unaffected.	  	  Local	  drug	  delivery	  achieves	  targeting	  by	  applying	  or	  delivering	  a	  drug	  
to	   the	   physical	   location	   of	   disease,	   thereby	   leaving	   normal	   structures	   free	   of	  
potential	  side	  effects.	  	  	  
	  
Modern	   medicine	   is	   rife	   with	   examples	   of	   pharmacologically	   targeted	   therapies.	  	  	  
Many	  antibiotics	  and	  chemotherapy	  agents	  selectively	  affect	  processes	  or	  molecules	  
exclusive	   to	   invasive	  microorganisms	  or	   tumor	  cells	  respectively.	   	  A	   few	  examples	  
include	   penicillin	   class	   antibiotics	   that	   interfere	  with	   bacterial	   cell	  wall	   synthesis,	  
tyrosine	   kinase	   inhibitors	   that	   disrupt	   replication	   of	   tumor	   cells,	   and	  monoclonal	  
antibodies	   directed	   against	   specific	   cell	   types	   such	   as	   the	   cell	   surface	   receptor	  
HER2/neu	   expressed	   in	   breast	   cancer,	   CD-­‐20	   in	   B	   cell	   lyphomas,	   and	   the	  
hematopoetic	   marker	   CD33	   for	   treatment	   of	   AML4.	   	   Pharmacologically	   targeted	  
therapies	   have	   recently	   revolutionized	   the	   treatment	   of	   autoimmune	   and	  
inflammatory	   diseases	   as	   well.	   	   Examples	   include	   monoclonal	   antibodies	   against	  
molecules	  implicated	  in	  the	  pathogenesis	  of	  these	  diseases	  such	  as	  anti-­‐TNF	  therapy	  
for	   rheumatoid	   arthritis5	   and	   inflammatory	   bowel	   disease6	   as	   well	   as	   the	  
monoclonal	   antibody	   natalizumab	   against	   alpha-­‐4	   integrin	   for	   the	   treatment	   of	  
multiple	  sclerosis7	  and	  Crohn’s	  disease8.	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Local	  drug	  delivery,	  although	  less	  frequently	  employed,	  is	  also	  used	  to	  increase	  the	  
specificity	   of	   pharmacological	   treatments.	   	   Due	   to	   ease	   of	   application,	   local	   drug	  
delivery	   is	   most	   frequently	   used	   for	   treatment	   of	   skin	   diseases.	   	   The	   respiratory	  
tract	  is	  another	  convenient	  site	  for	  local	  drug	  delivery.	   	  Common	  examples	  include	  
nasal	  delivery	  of	  anti-­‐inflammatory	  agents	  and	  vaccines	  as	  well	  as	  inhaled	  drugs	  for	  
the	  treatment	  of	  pulmonary	  diseases	  such	  as	  asthma.	  	  	  
	  
Despite	   the	   success	   of	   using	   local	   drug	   delivery	   to	   achieve	   targeting,	   it	   has	   been	  
difficult	  to	  implement	  in	  cases	  where	  the	  disease	  does	  not	  involve	  easily	  accessible	  
areas	  of	  the	  body	  such	  as	  the	  skin	  or	  respiratory	  tract.	  	  Several	  orally	  administered	  
therapies	  use	  the	  fact	  that	  they	  are	  not	  absorbed	  across	  the	  gut	  epithelium	  to	  their	  
advantage	  and	  are	  used	  to	  treat	  gastrointestinal	  illnesses.	  	  Examples	  of	  this	  strategy	  
include	   anti-­‐inflammatory	   formulations	   for	   the	   treatment	   of	   inflammatory	   bowel	  
disease9	   and	   antibiotics	   such	   as	   rifaxamin,	   nyastatin,	   and	   vancomycin	   against	  
pathological	  organisms	  in	  the	  gastrointestinal	  tract10,11.	  	  	  
	  
It	   has	   proven	   difficult	   to	   access	   other	   sites	   of	   the	   body	   for	   local	   drug	   delivery,	  
however.	  	  Methods	  for	  achieving	  local	  drug	  delivery	  to	  other	  sites	  are	  invasive	  and	  
undertaken	   only	   during	   the	   treatment	   of	   serious	   illness	   when	   the	   toxicity	   of	  
treatment	   makes	   it	   absolutely	   necessary	   to	   minimize	   side	   effects.	   	   For	   example,	  
neurosyphilis	   is	   often	   treated	  with	   intrathecally-­‐administered	   penicillin.	   	   Prostate	  
cancer	  can	  be	  treated	  by	  surgically	   implanting	  radioactive	  seeds	  within	  the	  tumor.	  	  
In	   2003,	   the	   FDA	   approved	   a	   therapy	   that	   incorporated	   the	   chemotherapeutic	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carmustine	  into	  a	  biodegradable	  wafer	  that	  is	  surgically	  implanted	  into	  the	  brain	  for	  
treatment	  of	  malignant	  gliomas12.	  	  This	  final	  example	  of	  local	  drug	  delivery	  has	  the	  
further	   advantage	   of	   utilizing	   a	   drug	  delivery	   vehicle	   that	   gradually	   releases	   drug	  
into	  the	  environment	  over	  time,	  called	  controlled	  release,	  resulting	  in	  steadier	  drug	  
levels	  and	  increased	  therapeutic	  efficacy	  13-­‐15.	  
	  
1.1.2- Nanoparticles as Drug Delivery Vehicles 
Nanoparticles	   refer	   to	   a	   class	   of	   engineered	   colloidal	   systems	   with	   physical	  
dimensions	  measured	  on	   the	  nanometer	   scale,	   typically	   less	   than	  1µm.	   	  There	  are	  
five	  major	  classes	  of	  nanoparticles;	  particles	  with	  polymeric	  matrices,	  particles	  with	  
inorganic	   matrices	   such	   as	   gold	   or	   silica,	   liposomal	   nanoparticles,	   viral	  
nanoparticles,	   and	  particles	   composed	   of	   carbon	  networks	   such	   as	   nanotubes16,17.	  	  
Each	   class	   of	   nanoparticle	   differs	   significantly	   with	   respect	   to	   physical	  
characteristics,	  biological	  activities,	  applications,	  and	  fabrication	  methods.	  	  Although	  
this	   thesis	  will	   focus	  exclusively	  on	  polymeric	  nanoparticles,	  many	  of	   the	  concepts	  
described	  below	  are	  applicable	  to	  most	  or	  all	  of	  the	  nanoparticle	  classes16.	  
	  
A	   nanoparticulate	   drug	   delivery	   system	   is	   created	   by	   fabricating	   particles	   that	  
incorporate	  drug	  into	  the	  interior	  of	  the	  particle,	  a	  process	  called	  encapsulation	  or	  
drug	  loading17.	   	  The	  matrix	  of	  the	  particle	  is	  chosen	  such	  that	  it	  degrades	  in	  a	  time	  
dependent	  manner,	  often	  via	  hydrolytic	  cleavage	  with	  water	  molecules	  so	  that	  drug	  
release	  occurs	  when	  particles	  are	   in	  an	  aqueous	  environment,	  releasing	  drug	  from	  
its	  core	  and	  into	  the	  vicinity	  (see	  Figure	  1)18.	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Figure	  1-­‐	  Schematic	  representation	  of	  drug	  loaded	  nanoparticle.	  	  Encapsulated	  drug	  
is	  released	  upon	  degradation	  of	  particle	  matrix,	  in	  this	  case	  via	  hydrolysis.	  
	  
Nanoparticles	   have	   been	   under	   investigation	   for	   several	   decades	   and	   many	  
properties	   that	  make	   them	   ideal	   for	   local	   drug	   delivery	   have	   been	   characterized.	  	  	  
One	   advantage	   is	   the	   ability	   to	   fabricate	   particles	   of	   various	   sizes,	   affecting	  
biodistribution19,	   bioavailability20,	   excretion21,	   and	   trafficking	   across	   biological	  
barriers22,23.	  	  	  Another	  advantage	  is	  the	  ability	  to	  adjust	  the	  composition	  of	  particle	  
matrices	   in	   order	   to	   alter	   the	   kinetics	   of	   drug	   release24,25.	   	   Particles	   can	   also	   be	  
loaded	  with	  a	  variety	  of	  therapeutic	  and	  imaging	  agents	  simultaneously,	  allowing	  for	  
a	   multimodal	   diagnostic	   and	   treatment	   approach26.	   	   Finally,	   particles	   can	   be	  
fabricated	  from	  a	  wide	  variety	  of	  polymers,	  many	  of	  which	  are	  non-­‐toxic	  and	  have	  
already	  been	  approved	  for	  clinical	  use	  in	  humans	  by	  the	  FDA27,28.	  	  	  	  
	  
Perhaps	  the	  most	  intriguing	  property	  of	  nanoparticles	  is	  their	  ability	  to	  deliver	  drug	  
to	  specific	  sites	  or	  cell	  types	  within	  the	  body,	  thereby	  being	  useful	  in	  achieving	  local	  
drug	   delivery29.	   	   As	   previously	   discussed,	   drug	   loaded	   nanoparticles	   release	   the	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time	  dependent	  manner.	  	  Particles	  can	  be	  fabricated	  to	  encapsulate	  a	  high	  density	  of	  
drug	  within	  the	  core,	  making	  it	  possible	  to	  achieve	  high	  local	  concentrations	  of	  drug	  
in	  the	  immediate	  vicinity	  of	  the	  particle	  as	  it	  is	  releasing	  its	  contents29.	  	  In	  vivo,	  drug-­‐
loaded	  nanoparticles	  within	  close	  proximity	  to	  a	  site	  of	  disease	  would	  deliver	  a	  high	  
local	  concentration	  and	  low	  systemic	  concentration	  of	  drug,	  maximizing	  treatment	  
efficacy	  and	  minimizing	  systemic	  side	  effects.	  
	  
Physical	   localization	  of	  particles	   to	   sites	  of	  disease	  or	   to	   specific	   cell	   types	   can	  be	  
achieved	   through	   a	   variety	   of	  mechanisms.	   	   The	   simplest	   of	   these	  mechanisms	   is	  
called	   “passive	   targeting”,	   in	  which	   particles	   localize	   to	   sites	   of	   disease	   purely	   by	  
virtue	  of	  their	  small	  size30.	  	  The	  best-­‐characterized	  type	  of	  passive	  targeting	  is	  called	  
the	  Enhanced	  Permeability	   and	  Retention	  Effect	   (EPR).	   	   EPR	  occurs	   in	   areas	  with	  
leaky	   vasculature	   and	   impaired	   lymphatic	   drainage	   associated	   with	   solid	   tumors	  
and	   sites	   of	   inflammation,	   allowing	   for	   the	   preferential	   accumulation	   of	  
nanoparticles	  in	  these	  sites31,32.	  	  	  
	  
Passive	  targeting	  also	  occurs	  to	  the	  intestinal	  mucosa	  for	  orally	  delivered	  particles.	  	  
Nanoparticles	  have	  been	  shown	  to	  be	  retained	  within	  the	  gastrointestinal	  tract	  in	  a	  
manner	   inversely	   proportional	   to	   their	   size33,34.	   	   Furthermore,	   it	   has	   been	  
demonstrated	   that	   nanoparticles	   localize	   specifically	   to	   areas	   of	   inflammation	   in	  
animals	  models	  of	  colitis35,36.	   	  Authors	  have	  postulated	  that	   the	  mechanism	  of	   this	  
selective	   retention	   is	   increased	   mucous	   production	   and	   greater	   number	   of	  
phagocytic	   cells	   in	   areas	   of	   inflammation,	   specifically	   macrophages35,36.	   	   	   When	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loaded	   with	   therapy,	   orally	   delivered	   nanoparticles	   demonstrate	   increased	  
therapeutic	   efficacy	   and	   decreased	   systemic	   side	   effects	   over	   free	   drug	   in	   the	  
treatment	  of	  animal	  models	  of	  colitis37,38.	  
	  
Localization	  of	  particles	  to	  organs	  or	  cell	  types	  that	  may	  not	  be	  conducive	  to	  passive	  
targeting	   can	   be	   achieved	   via	   active	   targeting	   in	   which	   the	   particle	   surface	   is	  
functionalized	   with	   targeting	   ligands39.	   	   Equipped	   with	   these	   targeting	   moieties,	  
particles	   may	   act	   as	   “homing	   devices”	   to	   specific	   sites	   of	   disease29.	   	   Typically,	  
targeting	   ligands	  are	   chosen	   that	  have	  a	  high	  binding	  affinity	   to	   surface	   receptors	  
expressed	   by	   specific	   cell	   types	   such	   that	   the	   particle	   will	   preferentially	   bind	   to	  
individual	  targeted	  cells	  to	  the	  exclusion	  of	  others39.	  	  
	  
Various	   strategies	   exist	   for	   active	   targeting,	   the	   most	   common	   of	   which	   utilize	  
lectin-­‐glycoprotein,	   ligand-­‐receptor,	   and	   antibody-­‐antigen	   interactions.	   	   Lectin	  
targeting	   (carbohydrates	   on	   particle	   surface	   targeted	   to	   cell	   lectins)	   and	   reverse	  
lectin	  targeting	  (lectins	  on	  particle	  surface	  targeted	  to	  cell	  glycoproteins)	  represent	  
some	  of	  the	  earliest	  strategies	  for	  active	  targeting	  of	  nanoparticles40.	  	  A	  high	  degree	  
of	  cell	  specificity	  has	  been	  achieved	  by	  coating	  particles	  with	  artificially	  synthesized	  
polysaccharides	   that	   are	   tailored	   to	   bind	   lectins	   expressed	   on	   certain	   types	   of	  
cells40.	   	   Lectin-­‐glycoprotein	   targeting	   strategies	   have	   been	   shown	   to	   enhance	  
efficacy	   of	   nanoparticulate	   formulations	   of	   chemotherapy	   for	   colon	   and	   liver	  
cancer41,42,	   antibotics	   for	  H.	   pylori	   eradication43,	   and	  have	   even	  been	   evaluated	   in	  
vitro	   for	   colonic	   delivery	   of	   ondansetron	   for	   treatment	   of	   Irritable	   Bowel	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Syndrome44.	   	   In	   ligand-­‐receptor	  targeting,	  particles	  are	   functionalized	  with	   ligands	  
that	   bind	   to	   receptors	   overexpressed	   specifically	   by	   diseased	   tissue.	   	   The	   most	  
studied	   example	   is	   folate	   functionalized	   particles	   targeted	   against	   folate-­‐receptor	  
overexpressing	   tumors45-­‐47.	   	   Other	   examples	   of	   successful	   ligand-­‐receptor	   particle	  
targeting	   include	   the	   functionalization	   of	   antigen	   containing	   particles	   with	   TLR	  
agonists	   such	   as	   LPS	   and	   flagellin.	   	   Such	   particles	   have	   been	   shown	   to	   enhance	  
antigen	  delivery	  and	  enhance	  vaccination	  efficacy	   in	  vivo48,49.	   	  The	   final	  method	  of	  
active	   targeting,	   antibody-­‐antigen	   targeting,	   has	   been	   widely	   studied	   for	  
applications	  to	  cancer.	  	  Nanoparticles	  can	  be	  made	  to	  bind	  to	  certain	  cells	  with	  high	  
selectivity	  by	  decorating	  the	  particle	  surface	  with	  an	  antibody	  against	  a	  specific	  cell	  
surface	  marker.	   	  Examples	  of	  successful	  application	  of	  this	  strategy	  include	  studies	  
that	  target	  B	  cell	  lymphoma	  with	  particles	  conjugated	  to	  anti-­‐CD19	  and	  anti-­‐CD2050,	  
breast	  cancer	  cells	  with	  anti-­‐HER2	  functionalized	  particles51,52,	  and	  neuroblastoma	  
cells	  with	  anti-­‐GD2	   functionalized	  particles53.	   	  Antigen-­‐antibody	   targeting	  has	  also	  
been	   employed	   to	   shape	   immune	   responses	   by	   functionalizing	   IL-­‐2	   containing	  
nanoparticles	  with	  a	  stimulatory	  anti-­‐CD3	  antibody	  alongside	  peptide-­‐loaded	  MHCII	  
for	  stimulation	  of	  naïve	  T	  cells54.	  
	  
1.1.3- Nanoparticle Fabrication 
Nanoparticles	   have	   been	   manufactured	   for	   over	   two	   decades	   using	   a	   variety	   of	  
techniques55.	   	   Considerations	   when	   choosing	   between	   fabrication	   techniques	  
include	  the	  particle	  material,	  desired	  size,	  toxicity,	  ability	  to	  carry	  therapeutics,	  and	  
ability	  to	  add	  targeting	  ligands	  to	  the	  surface	  of	  the	  particle.	   	   	  The	  most	  commonly	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utilized	   methods	   for	   the	   fabrication	   of	   drug	   loaded	   particles	   include	   emulsion	  
chemistry56,	  spray	  drying57,	  and	  nanoprecipitation58.	  	  
	  
Emulsion	  techniques	  are	  especially	  conducive	  to	  drug	  encapsulation	  and	  allows	  for	  
high	   degrees	   of	   control	   over	   particle	   size	   and	   encapsulation	   efficiency	   while	  
remaining	   flexible	   enough	   to	   utilize	   a	   variety	   of	   particle	   materials	   and	  
encapsulants59.	  	  An	  emulsion	  refers	  to	  a	  mixture	  of	  two	  immiscible	  liquids	  in	  which	  
one	  liquid	  is	  dispersed	  as	  tiny	  droplets	  within	  the	  other.	  	  	  In	  this	  technique,	  particles	  
are	   formed	  within	  these	  small	  droplets	  of	  dispersed	  solvent.	   	  Emulsion	  techniques	  
take	  advantage	  of	  the	  fact	  that	  small	  droplets	  of	  predictable	  size	  are	  produced	  upon	  
the	   addition	   of	   mechanical	   energy	   to	   a	   mixture	   of	   two	   immiscible	   liquids.	   	   Solid	  
particles	  can	  be	  obtained	   from	  an	  emulsion	  when	   the	  particle	  matrix	  material	  has	  
differential	  solubilities	  between	  the	  two	  emulsion	  components.	  
	  
Typically,	  polymeric	  particles	  are	  produced	  by	  first	  dissolving	  the	  chosen	  polymer	  in	  
a	  small	  volume	  of	  volatile	  organic	  solvent.	  	  This	  organic	  solvent	  is	  then	  slowly	  added	  
to	  a	   larger	  volume	  of	  an	  aqueous	  solution	  of	  an	  amphiphilic	   stabilizer.	  Mechanical	  
energy	   is	   added	   to	   the	   system	   through	   stirring	   or	   sonication	  which	   disperses	   the	  
organic	  solvent	  containing	  the	  dissolved	  polymer	  matrix	  into	  tiny	  droplets,	  forming	  
an	  oil	   in	  water	  emulsion	  (denoted	  o/w,	   in	  which	   the	  smaller	  volume	  solution,	  and	  
hence	   that	   which	   is	   forming	   droplets,	   is	   written	   first).	   	   The	   viscosity	   of	   both	   the	  
organic	  and	  aqueous	  phase	  as	  well	  as	  the	  magnitude	  of	  mechanical	  energy	  put	  into	  
the	   system	   affect	   droplet	   size.	   	   As	   the	   droplets	   are	   produced,	   the	   amphiphilic	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stabilizer	   molecules	   associate	   with	   the	   surface	   of	   the	   particle	   and	   prevent	  
reassociation	  of	  droplets.	  	  The	  solution	  is	  then	  incubated	  to	  allow	  for	  evaporation	  of	  
the	  volatile	  solvent,	  and	  solid	  polymeric	  particles	  are	  left	  behind27.	  
	  
Particles	  can	  be	  fabricated	  to	  incorporate	  an	  encapsulant	  within	  the	  interior	  of	  the	  
particle27,60.	   	   Encapsulants	   with	   a	   similar	   solubility	   profile	   to	   that	   of	   the	   particle	  
matrix	   can	   be	   incorporated	   simply	   through	   addition	   to	   the	   initial	   particle	   matrix	  
solution.	   	   In	   the	   case	   of	   polymeric	   particles	   described	   above,	   hydrophobic	  
encapsulants	   can	   be	   dissolved	   along	  with	   the	   polymer	   in	   the	   organic	   phase.	   	   The	  
encapsulant	  will	  remain	  in	  the	  organic	  phase	  throughout	  particle	  fabrication	  along	  
with	   the	   polymer	   and	   will	   become	   incorporated	   within	   the	   particle	   matrix	   itself.	  	  
This	  is	  called	  a	  single	  emulsion	  (see	  Figure	  2).	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Figure	   2-­‐	   Schematic	   representation	   of	   single	   emulsion	   nanoparticle	   fabrication	  
where	   	  represents	  a	  polymer	  and	  •	  represents	  a	  drug.	  	  The	  drug	  and	  polymer	  are	  
dissolved	   in	   an	   organic	   solvent	   and	   added	   dropwise	   to	   a	   vortexing	   solution	   of	  
aqueous	   stablizer	   to	   form	   an	   oil-­‐in-­‐water	   emulsion.	   	   Probe	   sonication	   produces	  
nano-­‐sized	   droplets	   of	   organic	   solvent	   containing	   dissolved	   drug	   and	   polymer.	  	  
Evaporation	  of	  the	  organic	  solvent,	  washing,	  and	  lyophilization	  yields	  spherical	  drug	  
loaded	  polymeric	  nanoparticles.	  	  
	  
Encapsulants	  with	  a	  dissimilar	  solubility	  profile	  to	  that	  of	  the	  particle	  matrix	  can	  be	  
incorporated	   using	   a	   double	   emulsion	   technique.	   	   This	   technique	   is	   called	   double	  
emulsion	  because	  the	  steps	  outlined	  above	  are	  repeated	  twice,	  essentially	   forming	  
an	  emulsion	  of	  an	  emulsion.	  	  In	  this	  technique,	  a	  solution	  of	  the	  encapsulant	  that	  is	  
immiscible	  with	  that	  of	  the	  particle	  matrix	  is	  prepared	  first.	  	  This	  solution	  is	  added	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to	   the	   polymer	   matrix	   solution,	   mechanical	   energy	   is	   added,	   and	   an	   emulsion	   is	  
produced.	   	  This	  emulsion	  is	  then	  added	  to	  a	  larger	  volume	  of	  solution	  containing	  a	  
stabilizer	   as	   in	   the	   single	   emulsion	   technique.	   	   This	   is	   especially	   useful	   when	  
producing	   polymeric	   particles	   that	   contain	   proteins.	   	   Proteins	   are	   particularly	  
difficult	   to	   incorporate	   in	   polymeric	   particles	   because	   they	   are	   soluble	   only	   in	  
aqueous	  solutions	  and	  easily	  denature	  when	  they	  contact	  organic	  solvents.	  	  Protein	  
containing	   polymeric	   particles	   are	   fabricated	   by	   first	   adding	   an	   aqueous	   protein	  
solution	  to	  a	  solution	  of	  polymer	  in	  volatile	  organic	  solvent	  and	  forming	  a	  water-­‐in-­‐
oil	   emulsion	   (w/o).	   	   This	   w/o	   emulsion	   is	   then	   added	   to	   a	   large	   volume	   of	   a	  
stabilizer	   containing	   aqueous	   solution,	  mechanical	   energy	   is	   added,	   and	   a	   second	  
emulsion	   is	   produced	   called	   a	   water-­‐in-­‐oil-­‐in-­‐water	   double	   emulsion	   (denoted	  
w/o/w	   emulsion).	   	   As	   above,	   the	   mixture	   is	   incubated	   to	   allow	   for	   solvent	  




	  In	   order	   to	   defend	   against	   a	   wide	   array	   of	   pathogens,	   the	   immune	   system	   has	  
developed	   potent	   mechanisms	   to	   identify	   and	   destroy	   invaders.	   	   However,	   these	  
mechanisms	  have	  the	  potential	  to	  damage	  the	  host	  and	  it	  therefore	  becomes	  critical	  
that	   the	   immune	  system	  be	  able	  to	  discriminate	  between	  self	  and	  non-­‐self61.	   	   	  The	  
immune	  system’s	  natural	  aversion	  to	  self	  destruction	  was	  originally	  termed	  horror	  
autotoxicus	  in	  189762,	  literally	  meaning	  “the	  horror	  of	  self-­‐toxicity”.	  	  The	  concept	  of	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horror	   autotoxicus	   is	   represented	   today	   in	   the	  multiple	  mechanisms	   employed	   by	  
the	  immune	  system	  to	  discriminate	  self	  from	  pathogens,	  a	  process	  collectively	  called	  
self-­‐tolerance.	  	  Occasionally	  however,	  the	  mechanisms	  of	  tolerance	  can	  break	  down,	  
in	   which	   case	   the	   immune	   system	   becomes	   activated	   against	   self-­‐antigens,	   and	  
autoimmune	  disease	  ensues61.	  
	  
1.2.1- Mechanisms of Autoimmunity 
The	   induction	  of	  self-­‐tolerance	  begins	  early	   in	   the	   life	  of	  a	   lymphocyte.	   	   Immature	  
lymphocytes	  develop	  in	  the	  thymus	  or	  bone	  marrow,	  a	  place	  in	  the	  body	  that	  should	  
be	  pathogen	  free.	  	  Furthermore,	  the	  transcription	  factor	  AIRE	  is	  responsible	  for	  the	  
expression	   of	   many	   peripheral	   proteins	   in	   the	   thymus63.	   	   Therefore,	   antigens	  
recognized	   by	   such	   developing	   lymphocytes	   are	   likely	   to	   be	   self	   antigen.	   Such	  
antigen	   recognition	   in	   immature	   lymphocytes	   leads	   to	   a	   negative	   signal	   and	   cell	  
death,	   a	  mechanism	   known	   as	   central	   tolerance64.	   	   Another	  mechanism	   by	  which	  
self-­‐tolerance	   occurs	   is	   that	   lymphocytes	   constantly	   recognizing	   high	   and	  
unchanging	   levels	   of	   antigen	   become	   tolerized.	   	   This	   occurs	   because	   levels	   of	  
pathogenic	   antigens	   should	   increased	   sharply	   following	   invasion	   and	   the	   levels	   of	  
antigen	   should	   fluctuate	   given	   the	   state	   of	   infection;	   antigens	   present	   at	   constant	  
high	  levels	  are	  likely	  to	  be	  self-­‐antigens.	   	  These	  self-­‐reactive	  cells	  are	  deleted	  from	  
the	  T	   cell	   repertoire	   via	   a	  process	   known	  as	   activation	   induced	   cell	   death	   (AICD),	  
process	   that	   is	  mediated	   by	   Fas/Fas-­‐ligand	   interactions65.	   	   A	   third	  mechanism	   of	  
tolerance	   is	   called	   peripheral	   tolerance	   and	   this	   acts	   on	  mature	   lymphocytes	   that	  
are	  circulating	   in	  the	  periphery.	   	   In	  order	  for	  a	   lymphocyte	  to	  become	  activated,	   it	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must	   receive	   co-­‐stimulatory	   signals	   from	   an	   antigen-­‐presenting	   cell.	   	   Uninfected	  
peripheral	   tissues	   do	   not	   express	   co-­‐stimulatory	   molecules,	   and	   therefore	  
lymphocytes	   that	   have	   escaped	   central	   tolerance	   and	   recognize	   an	   antigen	   in	   the	  
absence	   of	   a	   co-­‐stimulatory	   signal	   are	   likely	   autoreactive.	   	   This	   lack	   of	   co-­‐
stimulation	  leads	  to	  the	  cell	  becoming	  anergic	  and	  eventually	  cell	  death66.	  
	  
The	   process	   of	   maintaining	   self-­‐tolerance	   can	   be	   thought	   of	   as	   a	   series	   of	  
checkpoints	   that	   begin	   with	   the	   central	   deletion	   of	   self-­‐reactive	   immature	  
lymphocytes.	   	  None	  of	   these	  multiple	  checkpoints	  are	  100%	  efficient,	  however	  the	  
cumulative	  result	   is	  a	  system	  that	  can	  respond	  to	  pathogen	  while	  also	  maintaining	  
tolerance	   to	   self.	   	   In	   approximately	  5%	  of	  people	  however,	   these	  mechanisms	  are	  
insufficient	   and	   the	   immune	   system	   becomes	   activated	   against	   self-­‐antigens	  
resulting	  in	  autoimmune	  disease67.	  	  	  
	  
In	  rare	  cases,	  the	  autoimmunity	  is	  purely	  the	  result	  of	  genetic	  defects.	  	  For	  example,	  
mutations	   in	  Fas	  or	  Fas-­‐ligand	   that	   impair	   activation	   induced	   cell	  death	   results	   in	  
Canale-­‐Smith	   syndrome,	   an	   autoimmune	   syndrome	   in	   which	   patients	   suffer	   from	  
massive	   accumulation	   of	   T	   cells	   in	   lymphoid	   organs	   and	   express	   multiple	  
autoantibodies68.	  	  Another	  example	  of	  genetically	  determined	  autoimmunity	  is	  that	  
AIRE	   defects	   can	   lead	   to	   APECED	   (autoimmune	   polyendorinopath-­‐candidiasis-­‐
ectodermal	  dystrophy)	  in	  which	  patients	  have	  autoimmune	  destruction	  of	  multiple	  
endocrine	  organs69.	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Instances	   of	   pure	   genetic	   autoimmunity	   are	   rare	   however.	   	   It	   is	   now	   generally	  
accepted	   that	   autoimmunity	   most	   commonly	   develops	   as	   a	   result	   of	   genetic	  
predisposition	   and	   failure	   of	   intrinsic	   tolerance	   mechanisms	   in	   the	   setting	   of	  
environmental	   triggers	   (see	   Figure	   3)70.	   	   	   Examples	   of	   genetic	   predispositions	   to	  
autoimmunity	   include	   HLA-­‐B27	   and	   the	   associated	   high	   risk	   of	   ankylosing	  
spodylitis71,	  HLA-­‐DR3	  and	  HLA-­‐DR4	  that	  confer	  a	  20	  fold	  higher	  risk	  of	  developing	  
Type	  1	   diabetes72,	   and	  NOD2	  mutations	   that	   increase	   the	   risk	   of	   IBD73.	   	   Although	  
these	   genetic	   variances	   increase	   risk,	   they	   are	   not	   fully	   penetrant	   and	   thus	   not	  
everyone	  that	  has	  them	  will	  develop	  autoimmune	  disease.	  	  Another	  requirement	  is	  
the	  presence	  of	  lymphocytes	  capable	  of	  recognizing	  a	  self-­‐antigen.	   	  Since	  TCRs	  and	  
BCRs	   are	   produced	   through	   random	   recombination,	   the	   development	   of	  
autoreactive	  receptor	  specificity	  is	  largely	  due	  to	  chance70.	  
	  
Figure	  3-­‐	  Autoimmunity	  is	  often	  the	  result	  of	  a	  combination	  of	  factors.	   	  Genetically	  
predisposed	   individuals	   can	   develop	   autoimmune	   disease	   following	   an	  
environmental	   trigger	   and	   the	   failure	   of	   the	   intrinsic	   mechanisms	   of	   tolerance.	  	  
Adapted	  from	  70.	  
	  
Finally,	   development	   of	   autoimmunity	   can	   follow	   one	   or	   more	   environmental	  
triggers,	   most	   often	   an	   infection	   or	   some	   other	   inflammatory	   insult.	   	   Several	  
hypotheses	   exist	   as	   to	   how	   such	   triggers	   induce	   autoimmunity,	   although	   most	  
involve	  the	  activation	  of	  previously	  naïve	  lymphocytes	  with	  self-­‐reactive	  potential	  in	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the	  new	   inflammatory	  milieu.	   	   	   The	   theory	  of	  molecular	  mimicry	  postulates	   some	  
lymphocyte	  receptors	   that	  have	  high	  affinity	   for	  a	  pathogenic	  antigen	  may	  also	  be	  
weakly	   cross-­‐reactive	  with	   a	   self-­‐antigen	   that	   resembles	   the	  pathogenic	   antigen74.	  	  
During	  an	  infection,	  cells	  that	  express	  these	  receptors	  and	  become	  activated	  against	  
a	  pathogen	  can	  then	  go	  on	  to	  recognize	  and	  orchestrate	  a	  response	  against	  the	  self-­‐
antigen.	   	   	   For	   example,	   it	   is	   believed	   that	   rheumatic	   heart	   disease	   following	  
streptococcal	   infection	   results	   when	   activated	   T	   cells	   recognizing	   streptococcal	  
antigen	   cross	   react	  with	   antigens	   on	   heart	   valves,	   leading	   to	   tissue	   destruction75.	  	  
Another	  mechanism	  by	  which	  infection	  and	  inflammation	  can	  trigger	  autoimmunity	  
is	   by	   making	   intracellular	   antigens	   available	   to	   lymphocytes	   in	   the	   extracellular	  
environment.	   	   High	   rates	   of	   cell	   death	   during	   inflammation	   and	   large-­‐scale	   tissue	  
destruction	  such	  as	  myocardial	  infarction	  release	  intracellular	  antigens	  that	  can	  lead	  
to	  autoimmunity76.	  	  	  
	  
Once	  initiated,	  an	  autoimmune	  inflammatory	  reaction	  is	  often	  self-­‐sustaining	  given	  
the	   continuous	   presence	   of	   the	   antigen77.	   	   In	   fact,	   a	   phenomenon	   called	   epitope	  
spreading	   can	   occur	   in	  which	   the	   immune	   system	   becomes	   reactive	   to	  more	   and	  
more	   self-­‐antigens	   over	   time.	   	   It	   is	   thought	   that	   the	  disease	   begins	  with	   an	   initial	  
autoimmune	   reaction	   against	   a	   single	   inciting	   antigen	   but	   that	   the	   subsequent	  
recruitment	   of	   other	   inflammatory	   cells	   and	   production	   of	   pro-­‐inflammatory	  
cytokines	   can	   lead	   to	   increased	   availability	   and	   higher	   rates	   of	   activation	   against	  
additional	   self	   antigens78.	   	   An	   example	   of	   antigen	   spreading	   can	   be	   seen	   in	   the	  
disease	   systemic	   lupus	   erythematosis	   (SLE)79.	   	   Patients	   with	   SLE	   can	   express	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antibodies	  to	  multiple	  self-­‐antigens	  including	  anti-­‐dsDNA,	  anti-­‐Smith,	  anti-­‐Ro,	  anti-­‐
La,	  and	  anti-­‐nuclear	  antibodies.	  	  It	  has	  been	  observed	  that	  these	  antibodies	  develop	  
as	  the	  disease	  progresses	  and	  increases	  in	  severity80,81.	  
	  
The	  pattern	  of	  autoantibody	  production	  is	  often	  correlated	  with	  disease	  specificity	  
and	   symptomology.	   	   In	   general,	   autoimmune	   disease	   can	   be	   classified	   in	   two	  
categories:	  organ	  specific,	  and	  systemic.	  	  Organ	  specific	  autoimmune	  diseases	  affect	  
a	  single	  organ	  or	  cell	  type	  and	  are	  usually	  associated	  with	  individual	  autoantibodies	  
that	   are	   not	   widely	   expressed.	   	   For	   example,	   beta	   islet	   cell	   destruction	   in	   type	   1	  
diabetes	   is	  associated	  with	  antibodies	  directed	  against	   components	  of	  beta	  cells82,	  
Goodpasture’s	   syndrome	   is	   associated	   with	   anti-­‐glomerular	   basement	   membrane	  
antibodies83,	   and	  myasthenia	   gravis	   is	   associated	  with	   anti-­‐acetylcholine	   receptor	  
antibodies84.	   	   In	   contrast,	   systemic	   autoimmune	   diseases	   are	   associated	   with	  
ubiquitously	  expressed	  antigens	  such	  as	  DNA	  and	  RNA	   in	   the	  case	  of	  SLE85,	   IgG	   in	  
rheumatoid	  arthritis,	  and	  ribonuclear	  proteins	  in	  Sjogrens	  Syndrome86.	  	  
	  
1.2.2- Autoimmune Regulation by Tregs 
Autoreactive	  lymphocytes	  may	  avoid	  the	  negative	  selection	  process	  of	  tolerance	  but	  
still	  not	  cause	  overt	  disease.	   	  One	  mechanism	  of	  control	  over	  these	  cells	  is	  through	  
the	   action	   of	   a	   population	   of	   anti-­‐inflammatory	   regulatory	   T	   cells	   (Tregs).	   These	  
cells	  can	  be	  identified	  by	  their	  expression	  of	  the	  IL-­‐2	  receptor	  α-­‐chain	  CD25	  on	  their	  
surface	  and	  the	  transcription	  factor	  Foxp387.	   	  Two	  populations	  of	  Tregs	  have	  been	  
identified,	   natural	   Tregs	   (nTregs)	   and	   inducible	   Tregs	   (iTregs).	   	   nTregs	   are	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generated	  in	  the	  thymus	  where	  they	  begin	  expressing	  CD25	  and	  Foxp388.	  	  iTregs	  are	  
generated	   in	  the	  periphery	  when	  naïve	  T	  cells	  are	  activated	   in	  the	  presence	  of	   the	  
innate	  cytokine	  TGF-­‐β87.	  	  
	  
There	   are	   various	  mechanisms	   by	  which	   Tregs	  mediate	   their	   regulatory	   function.	  	  
Although	   they	   express	   the	   conventional	   antigen	   specific	   α:β	   T	   cell	   receptor	  
themselves,	   they	   are	   able	   to	   regulate	   the	   actions	   of	   T	   cells	   that	   bind	   a	   variety	   of	  
antigens	  as	  long	  as	  these	  cells	  are	  interacting	  with	  the	  same	  antigen	  presenting	  cell	  
(see	   Figure	   4)89.	   	   	   Tregs	   suppress	   inflammatory	   functions	   through	   both	   contact	  
dependent	  mechanisms	  involving	  membrane	  bound	  TGF-­‐β	  and	  the	  surface	  marker	  
CTLA-­‐4,	  as	  well	  as	  through	  the	  production	  of	  the	  anti-­‐inflammatory	  cytokines	  IL-­‐10	  
and	  TGF-­‐β,	  both	  of	  which	  serve	   to	  directly	  suppress	   the	  proliferation	  of	  T	  cells	  by	  
inhibiting	  the	  production	  of	  IL-­‐2,	  TNF-­‐α,	  and	  IL-­‐589.	   	  IL-­‐10	  also	  serves	  a	  regulatory	  
function	  by	  inhibiting	  antigen	  presentation	  and	  IL-­‐12	  production	  by	  dendritic	  cells,	  
thereby	   decreasing	   T	   cell	   activation	   and	   their	   subsequent	   differentiation	   into	  
inflammatory	  Th1	  cells89.	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Figure	  4-­‐	  Schematic	  of	  Treg	  actions.	  	  Treg	  cells	  can	  exert	  a	  regulatory	  function	  on	  T	  
cells	  that	  bind	  a	  variety	  of	  antigens.	   	  Tregs	  also	  inhibit	  the	  inflammatory	  actions	  of	  
antigen	  presenting	  cells	  through	  the	  production	  of	  IL-­‐10.	  	  Adapted	  from70	  
	  
It	  is	  now	  widely	  accepted	  that	  these	  actions	  of	  Tregs	  are	  central	  to	  the	  regulation	  of	  
inflammation	   and	   the	   suppression	   of	   autoimmune	   disease.	   	   Evidence	   of	   their	  
importance	   comes	   from	  both	   experimental	   animal	  models	   as	  well	   as	   from	  human	  
diseases.	   	   Transfer	   of	   Tregs	   has	   been	   shown	   to	   serve	   a	   protective	   role	   in	   the	  
CD4CD45RBhi	   T	   cell	   transfer	   model	   of	   colitis90,	   the	   Experimental	   Allergic	  
Encephalitis	   (EAE)	   model	   of	   multiple	   sclerosis91,	   and	   several	   animal	   models	   of	  
autoimmune	  diabetes92.	   	   In	  addition,	  depletion	  of	  Tregs	  has	  been	  demonstrated	   to	  
exacerbate	   existing	   disease	   and	   can	   even	   lead	   to	   fatal	   autoimmunity	   in	   animals93.	  	  
Studies	   of	   human	   type	   1	   diabetes	   have	   shown	   that	   Tregs	   from	   these	   patients	   are	  
ineffective	   at	   modulating	   the	   production	   of	   the	   cytokines	   TNF-­‐α	   and	   IFN-­‐γ	   by	  
inflammatory	   cells94.	   	   Defects	   in	   the	   regulatory	   activity	   of	   Tregs	   have	   also	   been	  
found	  in	  patients	  with	  rheumatoid	  arthritis95,	  multiple	  sclerosis96,	  and	  autoimmune	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polyglandular	   syndrome	   type	  297.	   	   Together,	   these	   findings	   all	   indicate	   that	   Tregs	  
play	  an	   important	  role	   in	  preventing	  the	   immune	  system	  from	  becoming	  activated	  
against	   self	   antigen	   and	   suggest	   interesting	   potential	   therapeutic	   targets	   and	  
modalities	  for	  the	  treatment	  of	  autoimmune	  disease.	  	  
	  
1.2.3- The Th17 Subset 
The	   differentiation	   of	   naïve	   T	   cells	   into	   distinct	   subsets	   is	   determined	   by	   the	  
cytokine	   milieu	   at	   the	   time	   of	   activation.	   	   These	   cytokines	   dictate	   the	   cell’s	  
subsequent	  actions	  since	  each	  subset	  has	  a	  unique	  effector	  phenotype.	   	  One	  of	   the	  
subsets	  produced	  early	   in	   the	   course	  of	   an	   infection	   is	   the	  Th17	  class	  of	  T	   cells98.	  	  
Naïve	  T	  cells	  become	  Th17	  cells	  when	  they	  are	  activated	   in	   the	  presence	  of	  TGF-­‐β	  
and	  IL-­‐6	  and	  express	  the	  master	  Th17	  transcription	  factor	  ROR-­‐γt99.	  	  The	  class	  gets	  
its	  name	  because,	  once	  differentiated,	  Th17	  cells	  produce	  high	  levels	  of	  IL-­‐17	  class	  
cytokines,	  namely	  IL-­‐17A	  (also	  simply	  called	  IL-­‐17),	  IL-­‐17B,	  IL-­‐17C,	  IL-­‐17D,	  IL-­‐17E	  
(also	  called	  IL-­‐25),	  and	  IL-­‐17F98.	  	  At	  rest,	  dendritic	  cells	  do	  not	  produce	  appreciable	  
amounts	   of	   IL-­‐6.	   	   However,	   in	   early	   infection,	   dendritic	   cells	   may	   increase	   IL-­‐6	  
production	   and	   also	   produce	   TGF-­‐β	   causing	   naïve	   T	   cells	   to	   differentiate	   towards	  
the	   Th17	   phenotype.	   	   This	   class	   of	   T	   cells	   is	   highly	   inflammatory	   and	   serves	   to	  
coordinate	  the	  inflammatory	  response	  once	  differentiated.	  	  They	  travel	  to	  the	  site	  of	  
infection	   where	   they	   produce	   IL-­‐17	   and	   IL-­‐22,	   which	   induce	   the	   production	   of	  
inflammatory	   cytokines	   by	   fibroblasts,	   epithelial	   cells,	   and	   keratinocytes.	   	   These	  
cells	   in	   turn	   produce	   IL-­‐6,	   granulocyte	   colony-­‐stimulating	   factor	   (G-­‐CSF)	   and	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granulocyte-­‐macrophage	   colony-­‐stimulating	   factor	   (GM-­‐CSF)	   which	   increase	  
neutrophil	  and	  macrophage	  production	  in	  the	  marrow,	  and	  CXCL8	  and	  CXCL2	  which	  
serve	  as	  neutrophil	  chemoattractants100,101.	  
	  
While	   these	  actions	  of	  Th17	  cells	   serve	  a	  physiological	   role	   in	   the	  defense	  against	  
pathogens,	   these	   highly	   inflammatory	   cells	   have	   been	   implicated	   in	   the	  
pathogenesis	  of	  a	  variety	  of	  autoimmune	  and	  inflammatory	  diseases102,103.	  	  The	  first	  
evidence	  of	   the	   importance	  of	  Th17	   cells	   in	   autoimmune	  pathogenesis	   came	   from	  
the	  study	  of	  the	  animal	  model	  of	  multiple	  sclerosis,	  EAE.	  	  At	  the	  time,	  it	  was	  believed	  
that	  EAE	  was	  largely	  a	  Th1	  mediated	  disease,	  however	  it	  was	  found	  that	  disease	  was	  
not	  ameliorated	  when	  the	  principle	  Th1	  cytokine	  IFN-­‐γ	  was	  removed	  via	  anti-­‐IFN-­‐γ	  
antibodies	   or	   genetic	   knockout104-­‐106.	   	   These	   findings	   suggested	   that	   another	   cell	  
type	   was	   at	   least	   partially	   responsible	   for	   the	   disease	   phenotype	   and	   further	  
investigation	  led	  to	  the	  subsequent	  identification	  of	  Th17	  cells	  as	  playing	  a	  central	  
role	   in	  EAE	   inflammation107,108.	   	  Additional	   support	   for	   the	   importance	  of	  Th17	   in	  
EAE	   pathogenesis	   came	   with	   the	   findings	   that	   animals	   treated	   with	   antibodies	  
against	   IL-­‐23,	   a	   cytokine	   that	   serves	   to	   expand	   previously	   differentiated	   Th17	  
cells102,	  and	  IL-­‐17	  deficient	  animals	  develop	  EAE	  with	  delayed	  onset	  and	  decreased	  
severity109,110.	  
	  
Further	   investigations	  have	   implicated	   the	   role	   of	   Th17	   cells	   in	   a	   variety	   of	   other	  
autoimmune	  and	  inflammatory	  diseases	  in	  both	  animal	  models	  and	  human	  patients.	  	  
Th17	   cells	   have	  been	   found	   to	   be	   critical	   in	   the	  development	   and	  maintenance	   of	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many	   of	   these	   diseases	   such	   as	   rheumatoid	   arthritis	   111,	   multiple	   sclerosis	   112,113,	  
inflammatory	   bowel	   disease102,114,	   SLE115,	   Sjögren’s	   Syndrome116,	   	   scleroderma117,	  
diabetes118,	  and	  even	  asthma119.	  These	  recent	  findings	  have	  generated	  considerable	  
interest	   in	   exploiting	  Th17	  cells	   and	  Th17	  cell	   associated	   cytokines	   for	   therapy	  of	  
these	  diseases.	  
	  
1.2.4- Retinoic Acid 
While	  other	  subsets	  of	  T	  cells	  undoubtedly	  play	  an	  important	  role	  in	  autoimmunity,	  
an	  imbalance	  between	  Th17	  cells	  and	  Tregs	  has	  been	  implicated	  in	  the	  pathogenesis	  
of	   many	   autoimmune	   and	   inflammatory	   diseases.	   	   An	   excessive	   inflammatory	  
reaction	  driven	  by	  Th17	  cells	  without	  proper	  regulation	  by	  Tregs	  is	  a	  major	  driving	  
factor	  in	  many	  of	  these	  conditions.	  	  Given	  that	  these	  cells	  types	  play	  such	  divergent	  
roles	  both	   in	   the	  healthy	   immune	  system	  and	   in	  autoimmunity,	   it	   is	   interesting	   to	  
note	  that	  development	  of	  each	  cell	  type	  is	  TGF-­‐β	  dependent.	  	  	  
	  
The	   common	   requirement	   of	   TGF-­‐β	   signaling	   for	   the	   production	   of	   two	   distinct	  
subsets	   of	   CD4+	   cells	   with	   such	   diverse	   roles	   prompted	   the	   investigation	   into	  
additional	  regulators	  of	  Th17	  and	  Treg	  cell	  differentiation.	  	  	  In	  particular,	  Mucida	  et	  
al.	   demonstrated	   that	   retinoic	   acid	   (RA)	  modulates	   T	   cell	   differentiation	   between	  
the	  Th17	  and	  Treg	   lineages	  by	  promoting	  the	  development	  of	  Treg	  cells	  and	  away	  
from	   Th17	   differentiation	   (see	   Figure	   5)120.	   	   Given	   the	   respective	   and	   largely	  
antithetical	   roles	  of	  Th17	  and	  Treg	  cells	   in	  autoimmune	   inflammation,	   it	  has	  been	  
speculated	   that	   RA	   could	   be	   used	   as	   an	   effective	   pharmacologically	   targeted	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immunotherapeutic	   agent	   for	   autoimmune	   conditions121-­‐123.	   	   Furthermore,	   RA	  
expressing	   DCs	   from	   the	   lamina	   propria	   of	   the	   gut	   have	   been	   shown	   to	   promote	  
Treg	   development	   and	   promote	   tolerance124	   while	   vitamin	   A125	   deficiency	   can	  
predispose	  to	  inflammation.	  	  To	  that	  end,	  it	  has	  recently	  been	  demonstrated	  that	  RA	  
is	   effective	   in	   decreasing	   disease	   burden	   in	   an	   animal	  model	   of	   colitis	   as	   well	   as	  
decreasing	  IL-­‐17	  production	  in	  cells	  from	  humans	  with	  ulcerative	  colitis126,127.	  
	  
Figure	   5-­‐	   Role	   of	   retinoic	   acid	   in	   T	   cell	   differentiation.	   	   TGF-­‐β	   is	   required	   for	   the	  
development	   of	   both	   regulatory	   T	   cells	   (Treg)	   and	   inflammatory	   Th17	   cells	   from	  
naïve	  CD4+	  T	  cells	  (Th0).	   	  Differentiation	  of	  Th0	  cells	   into	  Th17	  cells	  also	  requires	  
IL-­‐6.	  	  Retinoic	  acid	  regulates	  the	  differentiation	  of	  Th0	  cells	  by	  promoting	  Treg	  and	  
suppressing	  Th17	  development.	  
	  
RA,	   a	   derivative	   of	   vitamin	   A,	   is	   extensively	   used	   for	   the	   treatment	   of	   acute	  
promyelocytic	   leukemia128	  and	  dermatological	   conditions129.	   	   Studies	   involving	  RA	  
use	  in	  these	  conditions	  have	  shown	  that	  high	  doses	  of	  RA	  can	  induce	  the	  potentially	  
fatal	   reaction	   Retinoic	   Acid	   Syndrome130-­‐132	   as	   well	   as	   complications	   such	   as	  
myositis133,	   	   ascites134,	   and	   hypervitaminosis	   A,	   leading	   to	   hepatotoxicity,	   bone	  
abnormalities,	   and	  birth	  defects131,135.	   	   The	   incidence	   and	   severity	   of	   these	   effects	  
are	  directly	  related	  to	  serum	  concentration;	  however,	  it	  has	  been	  demonstrated	  that	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oral	   bioavailability	   of	   RA	   is	   extremely	   variable	   and	   unpredictable	   between	  
patients136.	  	  	  
	  
1.3- Statement of Hypothesis and Specific Aims 
RA	   is	   a	   promising	   pharmacologically	   targeted	   treatment	   for	   autoimmune	   and	  
inflammatory	  diseases.	   	  However,	  experience	  with	  the	  use	  of	  this	  drug	  in	  the	  clinic	  
has	  revealed	  significant	  shortcomings	  and	  difficulties	  with	  RA	  therapy.	  	  Therefore,	  a	  
vehicle	  for	  targeted	  localized	  delivery	  of	  RA	  to	  immune	  cells	  is	  highly	  desirable.	  
	  
Figure	  6-­‐	  Molecular	  structure	  of	  retinoic	  acid.	  
	  
As	   described	   in	   Section	  1.1.2,	   polymeric	   biodegradable	   nanoparticles	   are	   effective	  
drug	  delivery	  vehicles	  for	  achieving	  targeted	  local	  drug	  delivery.	  	  Examination	  of	  RA	  
structure	  reveals	  its	  hydrophobic	  nature	  (see	  Figure	  6)	  and	  RA	  does	  in	  fact	  dissolve	  
readily	   in	   organic	   solvent	   and	   has	   low	   water	   solubility137,	   making	   it	   an	   ideal	  
encapsulant	  for	  nanoparticles	  fabricated	  via	  the	  single	  emulsion	  o/w	  technique.	  	  The	  
polymer	   poly(lactic-­‐co-­‐glycolic	   acid)	   (PLGA)	   has	   a	   similar	   hydrophobicity	   profile	  
and	   degrades	   via	   hydrolytic	   cleavage,	  making	   it	   an	   appropriate	   choice	   of	   particle	  
matrix	   material	   for	   RA	   encapsulation.	   	   In	   addition,	   PLGA	   is	   non-­‐toxic	   and	   is	  
approved	  by	  the	  FDA	  for	  use	  in	  humans27.	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We	  propose	   to	  evaluate	   the	   feasibility	  of	  nanoparticulate	  drug	  delivery	  of	   retinoic	  
acid	   for	   the	   treatment	   of	   autoimmune	   and	   inflammatory	   diseases	   by	   creating	   RA	  
loaded	   PLGA	   nanoparticles.	   	   We	   hypothesize	   that	   RA	   delivered	   via	   PLGA	  
nanoparticles	  will	  be	  as	  effective	  or	  more	  effective	  at	  modulating	  immune	  responses	  
than	  soluble	  RA.	  	  We	  will	  evaluate	  this	  hypothesis	  according	  to	  the	  following	  specific	  
aims:	  
I-­‐ Fabricate	   RA	   loaded	   PLGA	   nanoparticles	   using	   a	   single	   emulsion	   o/w	  
technique,	  and	  characterize	  particle	  dimensions	  and	  pharmacokinetics.	  
II-­‐ Assess	  particle	  ability	  to	  modulate	  Th17	  and	  Treg	  differentiation	  relative	  
to	  soluble	  RA	  in	  vitro.	  




Materials and Methods 
2.1- Relative Contributions 
The	   entirety	   of	   the	   experiments	   described	   below	   were	   performed	   by	   the	   author	  
with	  the	  following	  exceptions;	   flow	  cytometry	  measurements	  of	   intracellular	  IL-­‐17	  
and	  ROR-­‐γ(t)	  in	  Th17	  cells	  were	  performed	  with	  Michael	  Look	  and	  Heba	  Nowyhed	  
(Figures	   10B	   &	   10C),	   the	   SEM	   image	   of	   PLGA	   nanoparticles	   was	   obtained	   by	   Dr.	  
Ragy	  Ragheb	  (Figure	  7B).	  	  
	  
2.2- Vehicle Fabrication and Characterization 
2.2.1- Particle Fabrication 
PLGA	  nanoparticles	  containing	  RA	  (Sigma-­‐Aldrich,	  R2625)	  were	   fabricated	  using	  a	  
single	   emulsion	   o/w	   technique.	   	   Briefly,	   200mg	   PLGA	   50/50	   with	   an	   average	  
molecular	  weight	  of	  80kD	  (Durect	  Corporation	  B6010-­‐2P)	  and	  0.751mg	  of	  RA	  were	  
dissolved	   in	  2ml	  of	   the	  volatile	  organic	  solvent	  dichloromethane	  (DCM).	   	  This	  was	  
added	   to	   4mL	   of	   a	   5%	   aqueous	   solution	   of	   the	   amphiphilic	   stabilizer	   poly(vinyl	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alcohol)	  (PVA)	  (Sigma-­‐Aldrich	  P1836)	  and	  sonicated	  three	  times	  for	  10	  seconds	  at	  
38%	   amplitude	   (TEKMAR	   VCW	   400W)	   on	   ice	   forming	   the	   o/w	   emulsion.	   	   The	  
mixture	  was	  incubated	  for	  1	  hour	  in	  100ml	  0.2%	  aqueous	  PVA	  and	  stirred	  to	  allow	  
for	   evaporation	   of	   the	   DCM	   and	   hardening	   of	   the	   nanoparticles.	   	   Particles	   were	  
collected	  via	  centrifugation	  at	  12000	  rpm	  at	  4°C	  and	  washed	   three	   times	  with	  de-­‐
ionized	  water	  to	  remove	  excess	  PVA.	  	  Particles	  were	  then	  lyophilized	  and	  stored	  at	  -­‐
20°C	  in	  an	  opaque	  container	  to	  protect	  RA	  from	  ambient	  light	  until	  use.	  	  
	  
2.2.2- Particle Characterization 
Particle	   size	   was	   determined	   using	   the	   nanoparticle	   tracking	   analysis	   instrument	  
Nanosight	  LM-­‐10	  (Nanosight	  LTD).	  	  	  The	  technique	  has	  been	  recently	  developed	  and	  
therefore	  will	  be	  described	  here.	  	  The	  instrument	  visualizes	  particles	  by	  illuminating	  
them	  in	  aqueous	  suspension	  using	  a	   laser	   light	  and	  a	  computer	  captures	  real-­‐time	  
video	  of	  particle	  motion.	  	  The	  particles	  are	  small	  enough	  such	  that	  their	  movement	  
is	   affected	   by	   the	   random	  motion	   of	   individual	  molecules	   on	   a	  microscopic	   scale.	  	  
This	  phenomenon	  is	  called	  translational	  diffusion	  or	  Brownian	  motion.	  	  Specialized	  
computer	  software	  tracks	  the	  motion	  of	  individual	  particles	  and	  generates	  a	  number	  
called	  a	  Diffusion	  Coefficient	  (D)	  which	  is	  directly	  proportional	  to	  the	  square	  of	  the	  
displacement	  of	  a	  particle	  per	  unit	  time.	  	  Observation	  of	  D	  allows	  the	  calculation	  of	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where	  kB	  is	  the	  Boltzman	  constant,	  T	  is	  the	  temperature,	  η	  is	  the	  viscosity,	  and	  R	  is	  
the	  particle	  radius.	  	  Concurrent	  measurement	  of	  the	  temperature	  determines	  T	  and	  
η,	  therefore	  allowing	  the	  particle	  radius	  R	  to	  be	  calculated.	  
	  
Particle	  morphology	  was	  observed	  with	  scanning	  electron	  microscopy.	  	  Loading	  was	  
determined	   by	   dissolving	   a	   predetermined	  mass	   of	   particle	   in	   dimethyl	   sulfoxide	  
and	  the	  amount	  of	  RA	  was	  quantified	  in	  the	  fully	  dissolved	  sample	  using	  absorbance	  
spectroscopy	  at	  360nm.	   	  Loading	  efficiency	  was	  calculated	  by	  dividing	  the	  mass	  of	  
RA	   present	   in	   particles	   by	   the	   amount	   of	   RA	   initially	   added	   in	   the	   particle	  
formulation	  and	  multiplying	  by	  100%.	  	  	  
	  
Pharmacokinetics	  of	  RA	  release	  was	  determined	  by	  adding	  an	  aqueous	  suspension	  
of	  RA	  loaded	  PLGA	  nanoparticles	  to	  dialysis	  cassettes	  (Pierce	  69590)	  placed	  in	  2L	  of	  
PBS	  on	  a	  rotary	  stirrer	  at	  37°C.	  	  Dialysis	  membranes	  with	  a	  MWCO=20,000kD	  were	  
used	  such	  that	  released	  RA	  molecules	  could	  freely	  diffuse	  out	  of	  the	  cassette	  but	  the	  
PLGA	  particles	  themselves	  along	  with	  any	  encapsulated	  RA	  were	  trapped	  within	  the	  
cassette.	   	   At	   various	   time	   points,	   the	   particle	   suspension	   within	   a	   cassette	   was	  
removed,	  particles	  were	  isolated	  via	  centrifugation,	  dissolved	  in	  dimethylsulfoxide,	  
and	  RA	  content	  determined	  spectrophotometrically	  using	  absorbance	  spectroscopy	  
at	   360nm.	   	   Amount	   of	   RA	   released	   as	   a	   function	   of	   time	   was	   determined	   by	  
calculating	  the	  difference	  between	  measured	  RA	  content	  and	  predicted	  RA	  content	  
based	  on	  particle	  loading.	  	  The	  dialysate	  was	  changed	  daily	  and	  each	  time	  point	  was	  
measured	  in	  triplicate.	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2.3- In Vitro Bioactivity 
2.3.1- Cell Culture and T cell Stimulation 
Six-­‐week-­‐old	  C57BL/6	  mice	  were	  purchased	  from	  Charles	  River.	  	  Mice	  were	  housed	  
under	  specific	  pathogen	  free	  conditions	  and	  used	  between	  7-­‐12	  weeks	  of	  age.	   	  The	  
spleen	  and	  axillary,	  cervical,	  and	  inguinal	  lymph	  nodes	  were	  removed.	  	  Lymphocytes	  
were	   isolated	  by	   combining	  organs	   and	   crushing	   them	   through	   a	  20µm	   filter	   into	  
sterile	  PBS.	  	  Cells	  were	  centrifuged,	  counted,	  and	  re-­‐suspended	  at	  a	  concentration	  of	  
10X109	   cells/mL.	   	   CD4+	   T	   cells	   were	   isolated	   using	   an	   Easy	   Sep	   CD4+	   T	   cell	  
enrichment	   kit	   (Stemcell	   Technologies,	   19752)	   according	   to	   the	   manufacturer’s	  
instructions.	  	  	  
	  
Once	   isolated,	  CD4+	  T	  cells	  were	  cultured	   in	  Click’s	  Media	   (Irvine	  Scientific,	  9195)	  
supplemented	   with	   10%	   heat	   inactivated	   FBS,	   2mM	   L-­‐glutamine,	   100U/ml	  
penicillin,	   100µg/ml	   streptomycin,	   and	   50µM	   β-­‐mercaptoethanol	   using	   cell	  
stimulation	   conditions	   adapted	   from	   previously	   described	   protocols120,138.	   	   Cells	  
were	   plated	   at	   a	   density	   of	   1X106	   cells/ml	   and	   volume	   of	   500µL/well	   in	   24	  well	  
plates	  or	  250µL/well	  in	  48	  well	  plates.	  	  	  Th17	  cells	  were	  generated	  by	  culturing	  cells	  
with	  1µg/ml	  anti-­‐CD3ε	  (BD	  Bioscience,	  553058),	  1µg/ml	  anti-­‐CD28	  (BD	  Bioscience	  
553295),	  20ng/ml	  IL-­‐6	  (Peprotech	  216-­‐16),	  and	  5ng/ml	  TGF-­‐β(Peprotech	  100-­‐21).	  	  
Treg	   cells	   were	   generated	   by	   stimulating	  with	   immobilized	   anti-­‐CD3ε	   (250	  µL	   of	  
10µg/ml),	  immobilized	  anti-­‐CD28	  (250	  µL	  of	  2µg/ml),	  and	  5ng/ml	  TGF-­‐β.	  	  Media	  for	  
Treg	  generation	  was	   identical	   to	   that	  used	   for	  Th17	  generation.	   	  RA	  or	  RA	   loaded	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PLGA	   nanoparticles	  were	   added	   at	   day	   0	   at	   the	   appropriate	   concentration.	   	   Cells	  
were	  cultured	  for	  5	  days	  in	  an	  incubator	  that	  maintained	  37°C	  at	  5%	  CO2.	  
	  
On	  day	  5,	  the	  cell	  suspension	  was	  collected	  and	  centrifuged	  in	  order	  to	  separate	  the	  
supernatant	   from	  cells.	   	   Cytokine	   content	  of	   the	   supernatant	  was	  quantified	  using	  
enzyme	   linked	   immunosorbant	   assay	   (ELISA).	   	   	   IL-­‐17	   (BD	  Bioscience	  555068	  and	  
555067)	  and	  IFN-­‐γ	  (BD	  Biosciences	  551309	  and	  551506)	  were	  measured	  for	  Th17	  
cells,	  and	  IL-­‐10	  (eBioscience	  88-­‐7104-­‐77)	   for	  Treg	  cells.	   	  The	  supernatant	  was	  not	  
diluted	  for	  the	  measurement	  of	  any	  cytokines.	  
	  
Th0	   cells	  were	  used	   as	  negative	   controls	   and	  were	   generated	  by	   stimulating	  with	  
soluble	   anti-­‐CD3ε	   (250	   µL	   of	   10µg/ml)	   and	   immobilized	   anti-­‐CD28	   (250	   µL	   of	  
2µg/ml)	  only.	  	  All	  other	  stimulation	  conditions	  for	  control	  cells	  were	  kept	  constant.	  	  
CD4+	   cells	   treated	   with	   PLGA	   nanoparticles	   not	   containing	   RA	   (blank)	   were	   also	  
used	   as	   negative	   controls.	   	   All	   animal	   care	   and	   experimentation	   were	   consistent	  
with	  NIH	  guidelines	  and	  approved	  by	  the	  Yale	  University	  Institutional	  Animal	  Care	  
and	  Use	  Committee.	  
	  
2.3.2- Flow Cytometry Analysis 
On	   day	   5	   of	   culture,	   CD4+	   cells	   were	   washed	   with	   Click’s	   media,	   resuspended	   in	  
media	   containing	   20ng/ml	   PMA,	   2000ng/ml	   ionomycin,	   and	   1µL/ml	   Golgi	   Plug	  
(BDBioscience	   555028),	   and	   incubated	   for	   6	   hrs.	   	   Cells	   were	   washed	   and	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resuspended	  in	  staining	  buffer	  containing	  1XPBS	  and	  2%	  BSA.	  	  Anti-­‐CD4	  conjugated	  
to	   Pacific	   Blue	   (BD	   Bioscience	   558107)	   and	   anti-­‐TCRβ	   conjugated	   to	   APC780	  
(eBioscience	  47-­‐5961-­‐80)	  were	  added	  and	  cells	  were	   incubated	  for	  30	  minutes	  on	  
ice	   for	   surface	   staining.	   	   Cells	   were	   permeabilized	   using	   Cytofix/Cytoperm	   Plus	  
Fixation-­‐Permeabilization	   Kit	   (BDBioscience	   555028)	   according	   to	   the	  
manufacturer’s	   instructions	   and	   stained	   with	   anti-­‐IL-­‐17	   conjugated	   to	   Alexa647	  
(eBioscience	   51-­‐7177-­‐80),	   anti-­‐ROR-­‐γ(t)	   conjugated	   to	   PE	   (eBioscience	   12-­‐6988),	  
and	  anti-­‐Foxp3	  conjugated	   to	  Alexa700	   (eBioscience	  56-­‐5773-­‐80)	   for	   intracellular	  
staining.	   	   Analysis	   was	   performed	   the	   same	   day	   using	   a	   LSRII	   Flow	   Cytometer	  
(Becton-­‐Dickinson	  and	  Company).	  	  	  
	  
2.3.3- Fibroblast/Th17 co-culture 
NIH	  3T3	   fibroblasts	  were	   cultured	   in	  hi-­‐glucose	  DMEM	  media	   supplemented	  with	  
10%	   heat	   inactivated	   FBS,	   100U/ml	   penicillin,	   and	   100µg/ml	   streptomycin	   and	  
allowed	   to	   adhere	   to	   the	   plate	   surface	   overnight.	   	   Cells	   were	   plated	   at	   a	   density	  
2X105	   cells/mL	   and	   a	   volume	   of	   1mL.	   	   T	   cells	   were	   polarized	   towards	   the	   Th17	  
phenotype	   and	   treated	   with	   10nM	   free	   RA	   or	   RA	   nanoparticles	   for	   5	   days	   as	  
described	   in	   Section	   2.3.1.	   	   Cells	   were	   subsequently	   washed,	   restimulated	   with	  
soluble	   1µg/ml	   anti-­‐CD3ε	   (BD	   Bioscience,	   553058)	   and	   1µg/ml	   anti-­‐CD28	   (BD	  
Bioscience	  553295),	  and	  added	  to	  the	  fibroblasts	  at	  a	  density	  of	  5X105	  cells/well.	  	  T	  
cells	  and	  fibroblasts	  were	  co-­‐cultured	  for	  24	  hrs,	  after	  which	  time	  supernatant	  was	  
collected	  and	  analyzed	  for	  IL-­‐6	  via	  ELISA	  (BD	  Biosciences	  550950).	  





3.1- Particle Characterization 
Particle	  sizing	  via	  the	  Nanosight	  LM-­‐10HS	  revealed	  an	  average	  particle	  diameter	  of	  
252nm	   with	   a	   mondisperse	   size	   distribution	   (see	   Figure	   7A).	   Observation	   of	  
particles	  via	  SEM	  revealed	  similarly	  sized	  spherical	  particles	  with	  a	  smooth	  surface	  
morphology	   all	   of	   roughly	   similar	   dimension	   (see	   Figure	   7B).	   	   Although	   not	  
quantitatively	   measured,	   the	   particle	   size	   distribution	   determined	   using	   the	  
Nanosight	  LM-­‐10HS	  correlates	  well	  to	  the	  size	  of	  particles	  visualized	  via	  SEM.	  	  
	  
	  
Figure	   7-­‐	   Nanoparticle	   characterization.	   	   (A)	   Hydrodynamic	   particle	   size	  
distribution	   as	   measured	   with	   Nanosight	   LM-­‐10HS	   reveals	   a	   monodisperse	  
distribution	  with	  average	  particle	  diameter=252nm.	  	  (B)	  SEM	  reveals	  similarly	  sized	  
spherical	  particles	  with	  smooth	  surface	  morphology.	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The	   control	   release	   curve	   of	   RA-­‐loaded	   nanoparticles	   determined	   using	   dialysis	  
reveals	  a	  biphasic	  release	  profile	  with	  an	  initial	  burst	  of	  RA	  release	  during	  the	  first	  
24-­‐48	  hours,	  followed	  by	  its	  slow	  gradual	  release	  in	  a	  plateau	  phase	  (see	  Figure	  8).	  	  
This	   type	  of	  biphasic	  release	   is	  a	   typical	  release	  profile	  observed	   in	  biodegradable	  
nanoparticulate	  systems.	  	  It	  has	  been	  speculated	  that	  the	  initial	  burst	  release	  is	  due	  
to	   release	   of	   surface	   associated	   encapsulant	   and	   the	   longer	   plateau	   phase	   is	   the	  
release	  of	  encapsulant	  truly	  incorporated	  within	  the	  particle	  matrix	  itself139.	  
	  
Figure	  8-­‐	  Drug	  release	  kinetics.	  	  Control	  release	  curve	  of	  RA	  from	  PLGA	  particles	  at	  
37°C	   in	   PBS	   reveals	   biphasic	   release	   kinetics	   with	   an	   initial	   burst	   release	   for	   24	  
hours	   followed	   by	   gradual	   release.	   	   Results	   shown	   are	   for	   triplicate	   samples	   and	  
error	  bars	  represent	  SEM.	  
	  
Loading	  of	  particles	  was	  2.29-­‐3.15	  µg	  RA/mg	  PLGA	  and	  loading	  efficiency	  was	  72.5	  
±	   11.5%.	   	   Such	   a	   high	   loading	   efficiency	   is	   expected	   when	   encapsulants	   possess	  
similar	  solubility	  characteristics	  as	  the	  particle	  matrix,	  in	  this	  case	  hydrophobic	  RA	  
and	  PLGA.	  	  Observed	  morphology	  via	  SEM,	  particle	  size	  distribution,	  control	  release	  
characteristics,	  and	  loading	  efficiency	  were	  similar	  for	  all	  batches	  of	  particles	  used	  
in	  experiments.	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3.2- In Vitro Bioactivity 
3.2.1- RA nanoparticles inhibit Th17 differentiation 
In	  order	  to	  assess	  the	  bioactivity	  of	  RA	  released	  from	  PLGA	  nanoparticles	  relative	  to	  
free	  compound,	  we	  cultured	  CD4+	  cells	  under	  Th17	  polarizing	  conditions138	   in	   the	  
presence	   of	  RA	  dissolved	   freely	   in	   solution	   or	   loaded	   in	   nanoparticles.	   	  We	   found	  
that	  both	  free	  RA	  and	  particulate-­‐encapsulated	  RA	  decreased	  the	  secretion	  of	  IL-­‐17	  
and	   IFN-­‐γ	   in	   a	   dose	   dependent	  manner	   (see	   Figure	   9).	   	   	   RA	   potency	  was	   similar	  
between	   free	   and	   particulate	   drug	   for	   concentrations	   of	   10nM,	   1nM,	   and	   0.01nM.	  	  
Free	  drug	  was	  more	  potent	  than	  nanoparticles	  at	  0.1nM.	  
	  
	  
Figure	  9-­‐	  Cytokine	  production	  of	  Th17	  cells.	  	  CD4+	  cells	  polarized	  towards	  the	  Th17	  
phenotype	   and	   treated	   for	   5	   days	   with	   soluble	   RA	   (free)	   and	   RA	   loaded	  
nanoparticles	   (NP)	   showed	   decreased	   production	   of	   IL-­‐17	   (A)	   and	   IFN-­‐γ	   (B).	   	   *	   =	  
p<0.05,	   separately	   comparing	   Th17	   cells	   treated	   with	   RA	   at	   the	   each	   indicated	  
concentration	  to	  Th17	  cells	  not	  treated	  with	  RA.	  The	  data	  represent	  5	  replicates	  and	  
the	  experiment	  was	  performed	  independently	  three	  times.	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In	   order	   to	   more	   closely	   investigate	   the	   phenotype	   of	   cells	   treated	   with	   RA,	   we	  
examined	   cells	   for	   Th17	   specific	   markers	   via	   flow	   cytometry.	   	   We	   observed	   that	  
CD4+TCR-­‐β+	   cells	   treated	  with	   free	   or	   encapsulated	   RA	   similarly	   expressed	   lower	  
levels	  of	   intracellular	   IL-­‐17	  and	  ROR-­‐γ(t),	   the	  key	   transcription	   factor	  of	   the	  Th17	  
lineage	  (see	  Figure	  10)140.	  	  	  
	  
Figure	  10-­‐	  FACS	  analysis	  of	  Th17	  cells.	  	  Flow	  cytometry	  revealed	  that	  RA	  treatment	  
decreased	  intracellular	  expression	  of	  IL-­‐17	  (A	  &	  B)	  and	  the	  key	  Th17	  transcription	  
factor	  ROR-­‐γ(t)	  (C).	  	  Flow	  cytometry	  plots	  are	  for	  [RA]=10nM	  	  *	  =	  p<0.05,	  separately	  
comparing	  Th17	  cells	  treated	  with	  RA	  at	  the	  each	  indicated	  concentration	  to	  Th17	  
cells	  not	   treated	  with	  RA.	  The	  data	  represent	  5	  replicates	  and	  the	  experiment	  was	  
performed	  independently	  three	  times.	  
	  
	  
3.2.2- RA nanoparticles enhance the Treg phenotype 
Since	   RA	   can	   enhance	   the	   development	   of	   Treg	   cells120,	   next	   we	   investigated	   the	  
effect	   of	   RA	   nanoparticles	   on	   cells	   cultured	   under	   conditions	   that	   promote	   T	  
regulatory	  cell	  differentiation.	  	  Free	  and	  PLGA-­‐encapsulated	  RA	  increased	  the	  IL-­‐10	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expression	  of	  Treg	  cells	  in	  a	  dose	  responsive	  manner	  (see	  Figure	  11);	  however,	  free	  
RA	   treatment	   resulted	   in	   greater	   increases	   in	   IL-­‐10	   production	   than	   did	  
nanoparticles.	  	  
	  
Figure	  11-­‐	  IL-­‐10	  production	  by	  Treg	  cells.	  	  CD4+	  cells	  treated	  with	  TGF-­‐β	  and	  treated	  
for	   5	   days	   with	   soluble	   RA	   (free)	   and	   RA	   loaded	   nanoparticles	   (NP)	   showed	  
increased	  production	  of	   IL-­‐10.	  *	  =	  p<0.05,	  separately	  comparing	  Treg	  cells	   treated	  
with	  RA	  at	  the	  each	  indicated	  concentration	  to	  cells	  not	  treated	  with	  RA.	  	  The	  error	  
bar	  on	  the	  blank	  condition	  is	  small	  and	  therefore	  not	  visible.	  The	  data	  represent	  5	  
replicates	  and	  the	  experiment	  was	  performed	  independently	  two	  times.	  
	  
Unlike	  IL-­‐10	  production,	  free	  RA	  and	  RA	  containing	  nanoparticles	  resulted	  in	  similar	  
increases	  in	  Foxp3	  expression,	  as	  measured	  by	  flow	  cytometry	  (see	  Figure	  12).	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Figure	   12-­‐	   FACS	   analysis	   of	   Treg	   cells.	   	   Flow	   cytometry	   reveals	   that	   cells	   treated	  
with	   RA	   have	   an	   increased	   expression	   of	   Foxp3.	   	   Histograms	   are	   shown	   for	   cells	  
treated	  with	  10nM	  RA.	  	  Blue=TGF-­‐β	  only,	  Red=	  TGF-­‐β	  and	  RA.	  *=p<0.05,	  comparing	  
treated	  to	  untreated	  cells.	  
	  
	  
3.2.3- RA nanoparticles inhibit IL-6 production in fibroblasts 
Th17	   cells	   promote	   inflammation	   and	   autoimmunity	   in	   part	   by	   inducing	   the	  
production	   of	   IL-­‐6	   in	   neighboring	   fibroblasts	   via	   IL-­‐17,	   thereby	   establishing	   a	  
positive	   feedback	   cycle	   favoring	   the	   development	   of	   more	   Th17	   cells101.	   	   We	  
therefore	   tested	   the	   ability	   of	   T	   cells	   treated	  with	   free	   and	   nanoparticulate	  RA	   to	  
trigger	   the	   production	   of	   IL-­‐6	   by	   fibroblasts	   in	   vitro	   (see	   Figure	   13).	   	   Whereas	  
fibroblasts	   treated	   with	   IL-­‐17	   alone	   or	   co-­‐cultured	   with	   Th17	   cells	   produced	  
significant	   amounts	   of	   IL-­‐6,	   those	   co-­‐cultured	   with	   T	   cells	   polarized	   towards	   the	  
Th17	  phenotype	   in	   the	  presence	  of	   free	  RA	  or	  nanoparticulate	  RA	  did	  not,	  with	   a	  
similar	  magnitude	  of	  suppression	  with	  both	  of	  these	  RA	  administration	  modalities.	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Figure	  13-­‐	  IL-­‐6	  production	  by	  fibroblasts.	  CD4+	  T	  cells	  were	  polarized	  towards	  the	  
Th17	  phenotype	  and	  treated	  with	  soluble	  RA	  or	  RA	  loaded	  PLGA	  nanoparticles	  for	  5	  
days,	  washed	  to	  remove	  excess	  RA	  or	  RA	  loaded	  NPs,	  and	  subsequently	  co-­‐cultured	  
with	  fibroblasts	  for	  24	  hours.	  	  IL-­‐6	  was	  then	  quantified	  in	  the	  supernatant	  by	  ELISA.	  	  
Fibroblasts	  treated	  with	  IL-­‐17	  or	  co-­‐cultured	  with	  Th17	  cells	  had	  higher	  production	  
of	   IL-­‐6	   than	   those	   co-­‐cultured	   with	   CD4+	   cells	   polarized	   towards	   the	   Th17	  
phenotype	   that	  were	  also	   treated	  with	  RA.	   	   ***=p<0.001,	   for	  comparison	  of	  any	  of	  
the	   three	   rightmost	   columns	   with	   any	   of	   the	   three	   leftmost	   columns.	   	   The	   data	  
represent	  3	  replicates.	  






In	   this	   work,	   we	   demonstrated	   a	   methodology	   for	   delivering	   bioactive	   RA	   in	   a	  
biodegradable,	   FDA	   approved	   polymeric	   nanoparticle	   format	   that	   can	   potentially	  
address	  issues	  related	  to	  delivery	  of	  this	  drug.	  	  RA	  released	  from	  our	  drug	  delivery	  
system	  is	  capable	  of	  reducing	  the	  production	  of	  Th17	  cells	  and	  increasing	  the	  Treg	  
phenotype	  of	  developing	  naïve	  T	  cells.	  	  Specifically,	  we	  showed	  that	  RA	  loaded	  PLGA	  
nanoparticles	  reduce	  IL-­‐17	  and	  IFN-­‐γ	  production	  and	  ROR-­‐γ(t)	  expression	  by	  CD4+	  T	  
cells	   exposed	   to	   IL-­‐6	   and	  TGF-­‐β	   in	   vitro	   as	  well	   as	   increase	   IL-­‐10	   production	   and	  
Foxp3	   expression	  by	  T	   cells	   treated	  with	  TGF-­‐β	   alone.	   	  We	   also	   demonstrate	   that	  
CD4+	   cells	   polarized	   towards	   the	   Th17	   phenotype	   have	   a	   dramatically	   reduced	  
ability	  to	   induce	  IL-­‐6	  production	  in	  fibroblasts	  when	  treated	  with	  RA	  loaded	  PLGA	  
nanoparticles.	   	  These	  findings	  are	  promising	  for	  the	  treatment	  of	  autoimmune	  and	  
inflammatory	  diseases	  driven	  by	  an	  excess	  of	  inflammatory	  Th17	  cells	  and	  a	  relative	  
deficiency	  of	  the	  anti-­‐inflammatory	  action	  of	  Treg	  cells.	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Our	  results	  show	  that	  the	  potency	  of	  RA	  delivered	  via	  PLGA	  nanoparticles	  is	  largely	  
equivalent	  to	  that	  of	  free	  drug	  in	  vitro.	   	  It	  should	  be	  noted	  that	  in	  our	  experiments,	  
concentrations	  of	  RA	  delivered	  to	  cells	  within	  particles	  was	  determined	  according	  to	  
particle	  loading	  and	  not	  the	  amount	  of	  RA	  released	  from	  the	  particles.	  	  Considering	  
the	   control	   release	   curve	   of	   RA	   from	   particles,	   cells	   treated	   with	   RA	   loaded	  
nanoparticles	  received	  only	  approximately	  80%	  as	  much	  RA	  as	   those	  cells	   treated	  
with	   free	  drug	  at	  a	  given	  concentration,	  demonstrating	  a	  moderate	   increase	   in	  RA	  
potency	  delivered	  via	  nanoparticle	  over	  free	  drug.	  	  	  
	  
In	   fact,	   increased	   bioactivity	   is	   commonly	   seen	   in	   molecules	   delivered	   via	  
particulate	  delivery	  systems	  relative	  to	  free	  drug	  both	  in	  vitro	  and	  in	  vivo29.	  	  	  In	  the	  
case	  of	  phagocytic	  cells	  such	  as	  macrophages	  and	  dendritic	  cells,	  a	  mechanism	  for	  
enhanced	   drug	   potency	   is	   that	   phagocytosed	   particles	   deliver	   high	   doses	   of	   drug	  
when	  degraded	  within	   the	  phagolysosome16.	   	   Such	   a	  mechanism	   is	   not	   evident	   in	  
non-­‐phagocytic	  cells	  such	  as	  T	  cells,	  however.	  	  It	  has	  been	  speculated	  that	  since	  drug	  
is	   being	   released	   from	  point	   sources	   rather	   than	   freely	   dissolved,	   it	   is	   possible	   to	  
achieve	   high	   local	   drug	   concentrations	   in	   the	   vicinity	   of	   the	   particle	   in	   a	  manner	  
similar	  to	  paracrine	  delivery54.	  	  Therefore	  in	  these	  experiments,	  T	  cells	  may	  receive	  
a	   relatively	   higher	   dose	   of	   RA	  when	   in	   close	   proximity	   to	   nanoparticles,	   possibly	  
explaining	  the	  observed	  moderate	  increase	  in	  drug	  potency.	  	  
	  
The	   experiments	   presented	  here	   have	  been	  designed	   to	   evaluate	   the	   feasibility	   of	  
nanoparticulate	  encapsulation	  and	  delivery	  of	  RA,	  not	  to	  demonstrate	  an	  advantage	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of	   nanoparticulate	   drug	   delivery	   over	   free	   drug	   per	   se.	   	   The	   many	   potential	  
advantages	   that	   targeted	   local	   drug	   delivery	   has	   over	   systemic	   administration	  
unfortunately	   cannot	   be	   easily	   reproduced	   in	   vitro.	   	   	   It	   is	   therefore	   necessary	   to	  
evaluate	  the	  efficacy	  of	  RA	  loaded	  nanoparticles	  relative	  to	  soluble	  RA	  in	  an	  animal	  
model	   of	   Th17	   mediated	   autoimmune	   disease	   in	   order	   to	   demonstrate	   the	   full	  
potential	  of	  our	  drug	  delivery	  platform.	  	  	  	  
	  
Models	   for	   testing	   of	   our	   platform	   include	   acute	   and	   chronic	   models	   of	   colitis,	  
rheumatoid	  arthritis,	  and	  multiple	  sclerosis.	  	  T	  cell	  models	  of	  arthritis	  that	  would	  be	  
conducive	   for	   testing	   advantages	   of	   RA	   loaded	   nanoparticles	   include	   the	   Collagen	  
Induced	  Arthritis	  (CIA)	  and	  SKG	  models141,142.	   	  These	  models	  are	  mediated	  by	  self-­‐
reactive	   Th17	   cells	   and	   represent	   an	   imbalance	   between	   inflammatory	   Th17	   and	  
regulatory	   T	   cell	   responses.	   	   Another	   animal	   model	   in	   which	   to	   test	   RA	   loaded	  
nanoparticles	  treatment	  is	  the	  EAE	  model	  of	  multiple	  sclerosis.	   	  Like	  the	  models	  of	  
arthritis,	  EAE	  is	  driven	  by	  Th17	  cells	  and	  would	  therefore	  be	  conducive	  to	  RA	  loaded	  
nanoparticulate	   treatment.	   	   Evaluation	   of	   our	   platform	   in	   these	   models	   could	   be	  
done	   by	   comparing	   therapeutic	   efficiency	   of	   drug-­‐loaded	   nanoparticles	   to	   that	   of	  
free	  RA	  administered	  systemically.	  	  Potential	  advantages	  of	  particles	  relative	  to	  free	  
drug	   in	   these	  models	   include	  higher	  drug	   residence	   time,	  more	   stable	   drug	   levels	  
due	  to	  controlled	  release	  of	  RA	  from	  particles,	  and	  localization	  of	  particles	  to	  areas	  
of	  inflammation	  secondary	  to	  leaky	  vasculature	  and	  inflammation	  via	  the	  EPR	  effect.	  	  
However,	  functionalization	  of	  the	  particle	  surface	  with	  T	  cell	  targeting	  ligands	  such	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as	   anti-­‐CD4	   antibodies	   could	   increase	   specificity	   of	   the	   particulate	   therapy	   even	  
further.	  
	  
Ease	  of	  particle	   targeting	  makes	   treatment	  of	   colitis	  with	  RA	   loaded	  nanoparticles	  
particularly	  intriguing.	  	  Currently,	  biologic	  therapy	  for	  IBD	  can	  only	  be	  administered	  
via	   injection143,	   however	   RA	   loaded	   nanoparticles	   would	   be	   orally	   administrable,	  
presenting	   a	   substantial	   improvement	   in	   patient	   comfort	   and	   convenience.	  	  
Furthermore,	  studies	  have	  shown	  that	  orally	  administered	  nanoparticles	  selectively	  
adhere	  to	  the	  intestinal	  epithelium	  and	  specifically	  localize	  to	  areas	  of	  inflammation,	  
allowing	  for	  high	  intestinal	  concentrations	  of	  drug	  that	  are	  difficult	  to	  achieve	  with	  
systemic	   therapy35,36.	   	   It	   has	   been	   demonstrated	   that	   adherent	   nanoparticles	   are	  
selectively	   retained	   within	   the	   GI	   tract,	   increasing	   their	   utility	   in	   IBD	   which	   is	  
associated	   with	   diarrhea	   and	   decreased	   residence	   time	   of	   orally	   administered	  
tablets35,36.	   	  This	  natural	   adherence	  and	   localization	   to	   inflamed	   intestinal	  mucosa	  
abrogates	   the	   need	   of	   any	   form	   of	   particle	   targeting	   via	   surface	   functionalization,	  
further	   increasing	   the	   appeal	   and	   simplicity	   of	   this	   approach.	   	   Specific	   T	   cell	  
mediated	  animal	  models	  of	  colitis	   include	   the	  acute	  colitis	  model	  TNBS	  colitis	  and	  
the	  chronic	  colitis	  model	  CD4+CD45RBhi	  T	  cell	  transfer	  model144.	  	  
	  
In	  summary,	  we	  have	  developed	  a	  novel	  biodegradable	  nanoparticulate	  vehicle	  for	  
the	   localized	   delivery	   of	   RA.	   	   We	   have	   demonstrated	   our	   ability	   to	   reproducibly	  
fabricate	   RA	   loaded	   PLGA	   nanoparticles	   with	   predictable	   time	   dependent	   drug	  
release	   kinetics.	   	   We	   have	   shown	   that	   the	   RA	   released	   from	   nanoparticles	   is	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bioactive	   and	   capable	   of	   altering	   the	   phenotype	   of	   developing	   T	   cells	   in	   vitro	  
similarly	   to	   free	  soluble	  RA.	   	  Our	   findings	  present	  a	  promising	   line	  of	   inquiry	   into	  
the	   usage	   of	   this	   novel	   formulation	   for	   autoimmune	   and	   inflammatory	   disease	  
therapy	  and	  represent	  the	  first	  step	  in	  the	  development	  of	  a	  therapeutic	  for	  clinical	  
use.	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